Integra LifeSciences Holdings (IART) revenue breakdown
By segment, Codman Specialty Surgical is the largest at 73% of fiscal 2025 revenue, growing 7% a year over 9 years.
By region, United States is the largest at 74% of fiscal 2025 revenue; Asia Pacific grew fastest, 14% a year over 9 years.
Revenue by segment
Fiscal years, as Integra LifeSciences Holdings reports them in its 10-K filings; fiscal 2025 total $1.6B.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Codman Specialty Surgical | $633M | $720M | $964M | $996M | $895M | $1.0B | $1.0B | $1.1B | $1.1B | $1.2B | 73% |
| Tissue Technologies | $360M | $468M | $509M | $521M | $477M | $517M | $538M | $483M | $467M | $435M | 27% |
Revenue by region
Fiscal years, as Integra LifeSciences Holdings reports them in its 10-K filings; fiscal 2025 total $1.6B.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $766M | $894M | $1.0B | $1.1B | $972M | $1.1B | $1.1B | $1.1B | $1.2B | $1.2B | 74% |
| Asia Pacific | $60M | $81M | $144M | $157M | $157M | $182M | $176M | $193M | $177M | $189M | 12% |
| Europe | $121M | $150M | $201M | $197M | $173M | $191M | $171M | $165M | $158M | $163M | 10% |
| Rest of the World | $46M | $63M | $81M | $85M | $70M | $80M | $83M | $83M | $83M | $79M | 5% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IART.
Open IART in InvestinglyQuestions
Where does Integra LifeSciences Holdings make its money?
In fiscal 2025, by segment: Codman Specialty Surgical $1.2B, Tissue Technologies $435M.
From Integra LifeSciences Holdings's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.